Santa Farma Pharmaceutical, one of the prominent players in the Turkish pharmaceutical sector, continues to strengthen its domestic and international standing through scientific research, advanced technology implementation, and strategic intellectual property management. According to the recently published data from "Turkey's Patent Report 2025" compiled by patent analytics firm Patent Effect, the company achieved remarkable positions across three core fields: pharmaceuticals, advanced materials, and European patent ecosystems. These metrics underscore the firm's multi-disciplinary research capabilities and systematic approach to contemporary chemical formulation.
Ranked Third Across Turkey in the Pharmaceutical Category
The company reinforced its market positions by steadily expanding its intellectual property assets in its primary field of operations. According to consolidated industry assessments, Santa Farma secured 3rd place among all corporate entities in Turkey with a total of 67 patent applications. This steady volume of filings highlights the brand's ongoing commitment to optimize formulation engineering and chemical synthesis pipelines within generic and specialized medicine.
Top 10 Distinction Achieved in Cross-Industry Advanced Materials Sector
The technical workflows spearheaded by the company's R&D division have yielded results extending well beyond classical pharmaceutical fields. In the sector-agnostic "Advanced Materials" evaluation of Turkey's Patent Report 2025, Santa Farma secured a position within the "Top 10" list by recording 41 patent filings. This cross-disciplinary approach validates the manufacturer's advanced engineering capacity in synthesizing novel polymer configurations and functional materials.
Furthermore, maintaining its steady presence in global intellectual property networks, the company filed 4 European Patents (EP) with the European Patent Office (EPO). This achievement positions the company among the elite group of Turkish firms recognized as "European Patent Champions," strengthening its corporate footprint in the global biomedical arena.
"We Will Continue to Drive Global Standards in Strategic R&D Investments"
Emphasizing the vital function of scientific investments and intellectual property frameworks within the corporate ecosystem, Ersin Yıldırım, R&D Director at Santa Farma Pharmaceutical, noted the following:
Drawing strength from our deep-rooted history of over 80 years, we advance every day toward our goal of being a reference company that brings local market needs together with global standards. A distinct reflection of this steady ascent is our verified success in 'Turkey's Patent Report 2025.' Ranking at the top not only in pharmaceuticals but also in alternative disciplines such as advanced materials proves that our capacity to build quality, innovative healthcare solutions spans a highly diverse technical spectrum. Backed by our robust engineering talent, state-of-the-art facilities, and strategic capital expenditure in R&D, we will continue to drive differentiation across the industry.
